Capsule enteroscopy is useful for the therapeutic management of Crohn’s disease

Table 1 Baseline characteristics of the patients included in the study n (%)

Population characteristics (n= 106)	Value
Male gender	47 (44)
Age - mean	40 ± 13 yr
Median time between diagnosis and VCE	5.5 (IQR 2-10) yr
Montreal classification
Age at diagnosis
A1: Below 17	7 (7)
A2: 17-40	84 (79)
A3: Above 40	15 (14)
Behavior
B1: Non-stenosing/non-penetrating	86 (81)
B2: Stenosing	12 (11)
B3: Penetrating	8 (8)
Location
L1: Terminal ileum	74 (70)
L2: Colonic	10 (9)
L3: Ileocolonic	22 (21)
+ L4: Upper disease	38 (36)
Treatment before VCE
Anti-TNF	21 (20)
Immunosuppressors	38 (36)
Aminosalicylates only	40 (38)
No treatment	7 (6)

VCE: Video capsule endoscopy; TNF-α: Tumor necrosis factor α.

Table 2 Patient characteristics at baseline that could influence therapeutic changes after video capsule endoscopy

Variable	Univariate analysis	Multivariate analysis
Age	P = 0.477	-
Male gender	P = 0.517	-
Smoking	P = 0.771	-
C-reactive protein	P = 0.188	-
Disease time duration	P = 0.073	-
Age at diagnosis	P = 0.097	-
Ileal vs colonic vs ileocolonic disease	P = 0.009	P = 0.367
Disease behaviour	P = 0.564	-